Clinical DevelopmentKIO-301 is set to enter a Phase 2 trial for retinitis pigmentosa, highlighting the progress in its clinical development.
Financial StabilityKiora has secured funding through 2026, which includes a substantial upfront from partnerships and private placements, providing financial stability.
Strategic PartnershipsKiora Pharmaceuticals entered into a strategic development and commercialization agreement with Théa Open Innovation, which will fund the remaining clinical development of KIO-301 across multiple indications.